Nicholas Keen

10.5k total citations · 2 hit papers
45 papers, 3.2k citations indexed

About

Nicholas Keen is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Nicholas Keen has authored 45 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 20 papers in Oncology and 13 papers in Cell Biology. Recurrent topics in Nicholas Keen's work include Microtubule and mitosis dynamics (13 papers), Monoclonal and Polyclonal Antibodies Research (12 papers) and Cancer-related Molecular Pathways (10 papers). Nicholas Keen is often cited by papers focused on Microtubule and mitosis dynamics (13 papers), Monoclonal and Polyclonal Antibodies Research (12 papers) and Cancer-related Molecular Pathways (10 papers). Nicholas Keen collaborates with scholars based in United Kingdom, United States and France. Nicholas Keen's co-authors include Stephen S. Taylor, Andrew Mortlock, Anthony Tighe, Trevor Johnson, Rebecca Ellston, Victoria Johnson, Kevin M. Foote, Claire Crafter, Frédéric Jung and Karen E. Gascoigne and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Nicholas Keen

39 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores

2003 980 citations Andrew Mortlock, Nicholas Keen et al. profile →
Aurora-kinase inhibitors as anticancer agents

2004 539 citations Nicholas Keen, Stephen S. Taylor Nature reviews. Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nicholas Keen United Kingdom	21	2.3k	1.9k	1.4k	262	186	45	3.2k
Lyubomir T. Vassilev United States	22	2.1k 0.9×	596 0.3×	1.4k 1.0×	86 0.3×	69 0.4×	37	2.8k
Hidehiko Kawai Japan	28	2.0k 0.9×	780 0.4×	1.5k 1.1×	62 0.2×	98 0.5×	61	2.7k
Rocı́o Sotillo Germany	23	2.6k 1.1×	1.6k 0.8×	1.7k 1.2×	189 0.7×	49 0.3×	40	3.7k
Kara M. Hoar United States	14	1.1k 0.5×	879 0.5×	780 0.6×	75 0.3×	140 0.8×	18	1.6k
Madhavi Bandi United States	11	1.2k 0.5×	744 0.4×	734 0.5×	133 0.5×	49 0.3×	20	1.9k
Beth A.A. Weaver United States	6	2.0k 0.9×	1.7k 0.9×	812 0.6×	299 1.1×	24 0.1×	6	2.6k
Paul J. Galardy United States	25	2.3k 1.0×	391 0.2×	971 0.7×	51 0.2×	97 0.5×	55	2.8k
Jingsong Yang United States	21	1.4k 0.6×	309 0.2×	898 0.6×	73 0.3×	68 0.4×	37	2.1k
Nicholas Kwiatkowski United States	31	3.2k 1.4×	478 0.2×	1.5k 1.1×	58 0.2×	120 0.6×	48	3.9k
Prasad V. Jallepalli United States	31	3.6k 1.6×	2.3k 1.2×	1.2k 0.9×	433 1.7×	38 0.2×	39	4.5k

Countries citing papers authored by Nicholas Keen

Since Specialization

Citations

This map shows the geographic impact of Nicholas Keen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicholas Keen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicholas Keen more than expected).

Fields of papers citing papers by Nicholas Keen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicholas Keen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicholas Keen. The network helps show where Nicholas Keen may publish in the future.

Co-authorship network of co-authors of Nicholas Keen

This figure shows the co-authorship network connecting the top 25 collaborators of Nicholas Keen. A scholar is included among the top collaborators of Nicholas Keen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicholas Keen. Nicholas Keen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Walsh, Stephen J., Johanna Lahdenranta, Philip Huxley, et al.. (2024). Abstract 5807: Bicycle Toxin Conjugates®for the treatment of solid tumors. Cancer Research. 84(6_Supplement). 5807–5807.

2.

Upadhyaya, Punit, Johanna Lahdenranta, Jun Ma, et al.. (2022). Discovery and Optimization of a Synthetic Class of Nectin-4-Targeted CD137 Agonists for Immuno-oncology. Journal of Medicinal Chemistry. 65(14). 9858–9872. 11 indexed citations

3.

Rigby, Michael, Gavin Bennett, Liuhong Chen, et al.. (2022). BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors. Molecular Cancer Therapeutics. 21(12). 1747–1756. 41 indexed citations

4.

Bennett, Gavin, Amy Brown, Gemma Mudd, et al.. (2020). MMAE Delivery Using the Bicycle Toxin Conjugate BT5528. Molecular Cancer Therapeutics. 19(7). 1385–1394. 77 indexed citations

5.

Hurov, Kristen E., Punit Upadhyaya, Johanna Lahdenranta, et al.. (2020). Abstract 5552: BT7480, a novel fully synthetic tumor-targeted immune cell agonist (TICATM) induces tumor localized 4-1BB agonism. Cancer Research. 80(16_Supplement). 5552–5552. 2 indexed citations

6.

Rigby, Mike, Paul Beswick, Gemma Mudd, et al.. (2019). Abstract 4479: BT8009: A bicyclic peptide toxin conjugate targeting Nectin-4 (PVRL4) displays efficacy in preclinical tumor models. Cancer Research. 79(13_Supplement). 4479–4479. 6 indexed citations

7.

Bennett, Gavin, Amy Brown, Gemma Mudd, Johanna Lahdenranta, & Nicholas Keen. (2019). Abstract 4481: BT5528, an EphA2-targeting Bicycle Toxin Conjugate (BTC): Profound efficacy without bleeding and coagulation abnormalities in animal models. Cancer Research. 79(13_Supplement). 4481–4481. 1 indexed citations

8.

Gibaja, Veronica, Joshua M. Korn, David A. Ruddy, et al.. (2015). Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors. Oncogene. 35(5). 558–566. 107 indexed citations

9.

Ferguson, Andrew D., Nicholas Larsen, Tina Howard, et al.. (2011). Structural Basis of Substrate Methylation and Inhibition of SMYD2. Structure. 19(9). 1262–1273. 154 indexed citations

10.

Keen, Nicholas & Stephen S. Taylor. (2009). Mitotic drivers—inhibitors of the Aurora B Kinase. Cancer and Metastasis Reviews. 28(1-2). 185–195. 52 indexed citations

11.

Foote, Kevin M., Andrew Mortlock, Nicola M. Heron, et al.. (2008). Synthesis and SAR of 1-acetanilide-4-aminopyrazole-substituted quinazolines: Selective inhibitors of Aurora B kinase with potent anti-tumor activity. Bioorganic & Medicinal Chemistry Letters. 18(6). 1904–1909. 32 indexed citations

12.

Goodlad, Robert A., Denis Alférez, Rajesh Odedra, et al.. (2007). Targeting aurora B kinase activity with AZD1152 leads to antitumor effects in preclinical models of intestinal cancer. Cancer Research. 67. 1640–1640. 1 indexed citations

13.

Girdler, Fiona, Karen E. Gascoigne, Patrick A. Eyers, et al.. (2006). Validating Aurora B as an anti-cancer drug target. Journal of Cell Science. 119(17). 3664–3675. 228 indexed citations

14.

Wilkinson, Robert W., Nicholas Keen, Rajesh Odedra, et al.. (2006). AZD1152: A highly potent and specific aurora kinase inhibitor.. Cancer Research. 66. 1333–1334. 6 indexed citations

15.

Mortlock, Andrew, Nicholas Keen, Frédéric Jung, et al.. (2005). Progress in the Development of Selective Inhibitors of Aurora Kinases. Current Topics in Medicinal Chemistry. 5(2). 199–213. 19 indexed citations

16.

Mortlock, Andrew, Nicholas Keen, Frédéric Jung, et al.. (2005). Progress in the Development of Selective Inhibitors of Aurora Kinases. Current Topics in Medicinal Chemistry. 5(8). 807–821. 62 indexed citations

17.

Keen, Nicholas, et al.. (2004). The Ipl1/Aurora Kinase Family: Methods of Inhibition and Functional Analysis in Mammalian Cells. Humana Press eBooks. 296. 371–382. 11 indexed citations

18.

Keen, Nicholas & Stephen S. Taylor. (2004). Aurora-kinase inhibitors as anticancer agents. Nature reviews. Cancer. 4(12). 927–936. 539 indexed citations breakdown →

19.

Keen, Nicholas. (1997). Transfer of Tat and release of TAR RNA during the activation of the human immunodeficiency virus type-1 transcription elongation complex. The EMBO Journal. 16(17). 5260–5272. 55 indexed citations

20.

Keen, Nicholas, et al.. (1993). Low Prevalence of Risk Factors for Coronary Heart Disease in Rural Tanzania. International Journal of Epidemiology. 22(4). 651–659. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact